DALLAS, Oct. 29, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotechnology company Jazz Pharmaceuticals Inc. (Nasdaq:JAZZ). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The investment report on Jazz Pharmaceuticals Inc. (Nasdaq:JAZZ) should be of particular interest to biotechnology companies: Cephalon Inc. (Nasdaq:CEPH), GlazoSmithKline plc. (NYSE:GSK) and Pfizer Inc. (NYSE:PFE).
It is available at: http://www.beaconequity.com/i/JAZZ
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Jazz Pharmaceuticals Inc. (JAZZ) engages in the development and commercialization of innovative products in the area of neurology and psychiatry in the United States. The Company's commercial products include Xyrem for the treatment of narcolepsy symptoms of daytime drowsiness and cataplexy; and Luvox CR for anxiety and obsessive compulsive disorders. The Company's product candidates presently in clinical trials include: JZP-6 (sodium oxybate) for the treatment of fibromyalgia; JZP-7 (transdermal ropinirole gel) for the treatment of restless legs syndrome; JZP-8 (intranasal clonazepam) for the treatment of recurrent acute repetitive seizures; and JZP-4 (sodium channel antagonist) for the treatment of epilepsy and bipolar disorder.
Message Board Search for JAZZ: http://www.boardcentral.com/boards/JAZZ
In the report, the analyst notes:
"JZP-6 (sodium oxybate), the active ingredient in Xyrem, is in the process of FDA clinical trials for the treatment of fibromyalgia-a diagnosis characterized by fatigue and muscle pain. Fibromyalgia afflicts approximately 3% of the U.S. adult population, or 6 million Americans (mostly females), according to the American College of Rheumatology.
"Currently, there is no effective treatment of fibromyalgia approved in the United States, Japan and Europe. According to the research firm, Datamonitor, the treatment of fibromyalgia is expected to reach approximately $1.7 billion in 2016."
To read the entire report visit: http://www.beaconequity.com/i/JAZZ
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.